• Cellvizio®
    • Overview
    • Education
    • Economics
  • Indications
    • Gastroenterology
      • Barrett’s Esophagus
      • Pancreatic Cystic Lesions
      • Gastric Disease
      • Inflammatory Bowel Diseases
      • Irritable Bowel Syndrome – Food Intolerance
      • Bilio-Pancreatic Strictures
      • Colorectal Lesions
    • Pulmonology
      • Lung Nodules
      • Lung Transplant
    • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Regulated Information
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Announces the Launch of CellTolerance® at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program 

Mauna Kea Technologies Announces the Launch of CellTolerance® at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program 

by Elizabeth | Nov 4, 2026 | News

Cleveland Clinic Abu Dhabi is ranked #1 for gastroenterology in the Middle East1  A highly promising commercial roll-out that provides access to one of the world’s highest-prevalence Irritable Bowel Syndrome (IBS) markets (~27% regional average2 vs. 9.2%...
Earlier, More Accurate Detection of Pancreatic Cancer

Earlier, More Accurate Detection of Pancreatic Cancer

by Elizabeth | Oct 30, 2026 | Press Coverage

Diagnosing pancreatic cancer and determining the risk associated with pancreatic cysts can be complex, often requiring multiple imaging studies, biopsies, and procedures. This episode of Medical Design Briefs podcast explores advances in diagnostic technologies that...
Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates 

Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates 

by Elizabeth | Oct 20, 2026 | News, News, News

Nine-month sales of €4.4 million, up 21% as reported and 24% at constant exchange rates (CER)  Europe and Rest of World up 128%, led by CellTolerance®, now present in 9 countries with 27 paying centers, up from 17 at end-2025  Third-quarter sales of €1.2 million, down...
Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates 

Mauna Kea Technologies Announces 2026 Half-Year Results 

by Elizabeth | Oct 8, 2026 | News

Product and service revenue of €3.2 million, up 37% driven by strong CellTolerance® momentum in Europe and new international markets  Gross margin on product and service revenue of 65%, up 2 points  Operating expenses1 of €5.9 million, with R&D and...
Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer 

Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer 

by Elizabeth | Aug 26, 2026 | News

Largest ever meta-analysis of upper gastrointestinal endomicroscopy pooling 33 studies and 2,350 patients  Original research conducted and funded by Korea’s National Evidence-Based Healthcare Collaborating Agency (NECA)  Authors document major clinical...
« Older Entries

Articles récents

  • Mauna Kea Technologies Announces the Launch of CellTolerance® at Cleveland Clinic Abu Dhabi, the First Hospital in the MENA Region to Offer the Program 
  • Earlier, More Accurate Detection of Pancreatic Cancer
  • Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates 
  • Mauna Kea Technologies Announces 2026 Half-Year Results 
  • Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal Cancer 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Cookie policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}